E
ESPR
Esperion Therape
2.17
0.04+1.88%After Hours: 2.180 +0.010 +0.46%19:57 08/22 EDT
OPEN/PREV CLOSE2.140/2.130
TODAY RANGE2.130-2.200
VOL4.94M
MARKET CAP437.52M
52 WEEK RANGE0.6925-3.940
AVG VOL (3M)4.57M
% TURNOVER2.45%
TURNOVER--
P/E (TTM)-4.0851
% RANGE3.29%
EPS(TTM)-0.5312
P/E(FORWARD)16.07
P/B-1.0019
BVPS-2.1659
DIVIDEND--
P/S1.279
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP435.15M
SHARES OUTSTANDING201.62M
NEXT EARNINGS11/05-11/10
FREE FLOAT200.53M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Dow Jones·08/14 10:37
*Correct: HLS Therapeutics Symbol HLS.T, Not HLT.T
Dow Jones·08/14 10:36
*HLS Therapeutics Still Sees 2025 Adjusted Ebitda $19.5M-$20.5M >HLS.T
Dow Jones·08/14 10:35
*HLS Therapeutics 2Q Rev $14.2M >HLT.T
Dow Jones·08/14 10:35
*HLS Therapeutics 2Q Loss/Shr 9c >HLT.T
Dow Jones·08/14 10:31
Press Release: HLS Therapeutics Announces Q2 2025 -2-
Dow Jones·08/14 10:31
Press Release: HLS Therapeutics Announces Q2 2025 Financial Results
TipRanks·08/11 22:08
Esperion Delays Q2 2025 Financial Report Filing
Reuters·08/11 20:11
Esperion Therapeutics Delays Q2 Financial Report Due to Identified Errors
Reuters·08/07 21:30
ESPERION ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Barchart·08/07 16:30
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Barchart·08/06 11:56
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises
TipRanks·08/06 04:32
Esperion Therapeutics Reports Strong Q2 2025 Growth
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.